Wed, 24/06/09 – 7:42 | No Comment

Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …

Read the full story »
Aim to Cure

A focus on disease-specific efforts by pharmaceutical and biotech companies

Analysis

Read in depth analysis by industry experts on investing opportunities and business strategies

Company Profiles

Learn about corporate strategies, positioning and investing opportunities

Industry News

Stay on top of the industry with our industry news bulletin

Mutual Funds

Diversify to hedge your investment during economic turbulence

Home » Archive by Category

Articles in Analysis

Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold In Patients With Late-Stage Leukaemia
Thursday, 18 Jun, 2009 – 2:00 | No Comment

Clavis Pharma ASA (OSE: CLAVIS) announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showed …

Three Rivers Announces Positive Results From Phase 3 DIRECT Trial Of Once-Daily INFERGEN(R) With Ribavirin In Hepatitis C Virus Treatment Failures
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

Three Rivers Pharmaceuticals announced positive results of the U.S.-based, randomized Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT) clinical trial authored by Bruce R. Bacon, M.D., of Saint Louis University, and colleagues at …

Three Rivers Announces Positive Results From Phase 3 DIRECT Trial Of Once-Daily INFERGEN(R) With Ribavirin In Hepatitis C Virus Treatment Failures
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

Three Rivers Pharmaceuticals announced positive results of the U.S.-based, randomized Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT) clinical trial authored by Bruce R. Bacon, M.D., of Saint Louis University, and colleagues at …

MacroGenics And Lilly Achieve Targeted Patient Enrollment In PROTEGE, A Global Phase 2/3 Clinical Trial Of Teplizumab In Type 1 Diabetes
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under …

MacroGenics And Lilly Achieve Targeted Patient Enrollment In PROTEGE, A Global Phase 2/3 Clinical Trial Of Teplizumab In Type 1 Diabetes
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under …

CeNeRx BioPharma Obtains Rights To Novel Drug Candidate For Prevention And Treatment Of Neurodegeneration Disorders
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), announced that it has obtained the rights to develop and market a novel agent for …

CeNeRx BioPharma Obtains Rights To Novel Drug Candidate For Prevention And Treatment Of Neurodegeneration Disorders
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), announced that it has obtained the rights to develop and market a novel agent for …

Abbott Initiates Trial Of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes From SPIRIT Family Of Trials
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

Abbott (NYSE: ABT) announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company’s next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the treatment …

Abbott Initiates Trial Of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes From SPIRIT Family Of Trials
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

Abbott (NYSE: ABT) announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company’s next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the treatment …

Data Presented At Society Of Nuclear Medicine 2009 Annual Meeting Supports Potential Of Peregrine’s Cotara(R) For The Treatment Of Brain Cancer
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that researchers will present data at the SNM 2009 Annual Meeting showing that its brain cancer agent Cotara(R) specifically localizes to brain tumors at high concentrations with minimal …

Data Presented At Society Of Nuclear Medicine 2009 Annual Meeting Supports Potential Of Peregrine’s Cotara(R) For The Treatment Of Brain Cancer
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that researchers will present data at the SNM 2009 Annual Meeting showing that its brain cancer agent Cotara(R) specifically localizes to brain tumors at high concentrations with minimal …

Pharma Enhances Patient Recruitment Methods Through Industry Site Level Dataset
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

KMR GROUP, a firm analyzing biopharmaceutical R&D performance since the early 1990s, announces SiteView, its newest module in the Enrollment Metrix Application. Enrollment Metrix helps companies plan more effectively and reliably when setting recruitment …

Pharma Enhances Patient Recruitment Methods Through Industry Site Level Dataset
Wednesday, 17 Jun, 2009 – 3:00 | No Comment

KMR GROUP, a firm analyzing biopharmaceutical R&D performance since the early 1990s, announces SiteView, its newest module in the Enrollment Metrix Application. Enrollment Metrix helps companies plan more effectively and reliably when setting recruitment …

India To Promote Drugs In Africa After Fake Chinese Drugs ‘Made In India’ Seized
Monday, 15 Jun, 2009 – 4:00 | No Comment

India launched a project to promote its $10.7 billion pharmaceutical industry in Africa after fake drugs labeled “Made in India,” but with actual origins in China were seized on the continent, IANS/Hindu reports. According to …

FDA Alerts Patients To Medtronic Pacemaker Recall
Sunday, 14 Jun, 2009 – 1:00 | No Comment

The U.S. Food and Drug Administration is alerting patients to the Class I recall of certain Medtronic Kappa and Sigma pacemakers. These devices may fail due to a separation of wires that connect the electronic …

Novo Nordisk Convenes Policy And Clinical Experts At Diabetes Media Summit
Saturday, 13 Jun, 2009 – 2:00 | No Comment

A distinguished panel of clinical and policy experts gathered by Novo Nordisk recently convened in Washington, D.C. to explore solutions to address the exponential growth of diabetes in America. The universal theme from the renowned …

Novo Nordisk Convenes Policy And Clinical Experts At Diabetes Media Summit
Saturday, 13 Jun, 2009 – 2:00 | No Comment

A distinguished panel of clinical and policy experts gathered by Novo Nordisk recently convened in Washington, D.C. to explore solutions to address the exponential growth of diabetes in America. The universal theme from the renowned …

New MedPredict Report Reveals Top Alzheimer’s Experts’ Insights On Diagnostics And Treatments In Development Pipeline
Saturday, 13 Jun, 2009 – 2:00 | No Comment

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Alzheimer’s Disease,” designed to provide critical strategic insight for pharma and …

New MedPredict Report Reveals Top Alzheimer’s Experts’ Insights On Diagnostics And Treatments In Development Pipeline
Saturday, 13 Jun, 2009 – 2:00 | No Comment

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Alzheimer’s Disease,” designed to provide critical strategic insight for pharma and …

Transcept Pharmaceuticals Announces Expected FDA Extension Of Regulatory Review Period For Intermezzo(R)
Saturday, 13 Jun, 2009 – 2:00 | No Comment

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced that the U.S. Food and Drug Administration (FDA) has informed the company that it should expect to receive formal notice of a three month extension of the review …